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Case report: 
A two-week old infant was transferred to our renal ward in February 2014 from the 
neonatal intensive care unit in her local hospital due to polyuria (~200ml/kg/day) 
and extreme acid-base and electrolyte disturbance from birth. She was born by 
spontaneous delivery at 32weeks gestation. Severe polyhydramnios was noted 
antenatally with two amniocenteses procedures removing over 6L fluid. She is the 
third child of consanguineous parents, with no relevant family history. 
Examination at admission was unremarkable; weight: 1.68kg (9thpercentile), length: 
44cm (25thpercentile), head circumference 29cm (5thpercentile), BP: 68mmHg 
systolic (normal). 
 
Initial investigations revealed a marked hypokalaemic (2.1mmol/l), hypochloraemic 
(59mmol/l) metabolic alkalosis (bicarbonate: 81mmol/l, pH: 7.8), leading to a 
presumptive diagnosis of Bartter syndrome (BS). Ultrasound showed echogenic 
kidneys without nephrocalcinosis. She remained polyuric with fragile intravascular 
volume status, reflected in plasma sodium values between 94-176mmol/L and 
recurrent episodes of acute kidney injury with creatinine levels between 29-
182umol/l. Sodium (14mmol/kg/day) and potassium (13mmol/kg/day) 
supplementation was provided with 200ml/kg/d of fluid to stabilise volume status, 
yet she had persistent severe alkalosis (pH 7.56-7.92). Concerns regarding 
respiration were first raised when she remained apnooeic after general anesthesia 
for a central line insertion and needed mechanical ventilation for 24hours. She was 
noted to have repeated desaturations and subsequent polysomnography 
demonstrated prolonged periods of cyclical dips (73dips/hour; normal <5) in oxygen 
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saturation (SpO2, see figure 1) with a mean and absolute nadir of 88% and 77%, 
respectively. Mean transcutaneous pCO2 was raised at 10kPa (75mmHg), maximum 
10.64kPa, and a respiratory rate of 10/min in periodic breathing, rising to 48 
breaths/minute in Quiet Sleep. The Apnoea-Hypopnoea Index was 68 central 
events/hour (normal <1, severe >10), with little evidence of obstruction (2/hour). 
Over the following year, she demonstrated profound global developmental delay 
with associated microcephaly, signs of delayed brain maturation on brain MRI and 
sensorineural hearing loss (SNHL, confirmed by auditory brainstem response). She 
had evidence of chronic kidney disease (CKD) from birth with an estimated GFR 
around 30ml/min/1.73m2. The patient also developed severe hypophosphataemic 
rickets, with plasma phosphate levels as low as 0.30 mmol/l, alkaline phosphatase 
levels up to 1226 U/l (normal 80-345) and renal phosphate wasting 
(TmP/GFR<0.83mmol/l; normal 1.10-2.70). 
BS is a genetically heterogeneous condition characterized by failure of renal 
reabsorption of sodium and chloride in the thick ascending limb of Henle’s loop 
(TAL)1. Prenatal onset, SNHL, normocalciuria and CKD are characteristic for BS type 
IV (BS4)2 and genetic testing confirmed this diagnosis by identification of a 
homozygous deletion in BSND c.452del; p.(Pro151Leufs*27). 
Hypokalaemic alkalosis in BS is secondary to increased aldosterone levels1, but was 
extreme in this case. The apneas and hypophosphataemic rickets were considered 
secondary complications. While respiratory suppression is well recognized as the 
physiological response to alkalosis3, hypophosphataemic rickets has to our 
knowledge not previously been reported. Yet, lower plasma phosphate levels have 
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been recurrently noted in alkalosis, including in BS, presumably due to the tight pH 
dependence of renal phosphate transporters4.  
Metabolic alkalosis carries significant risks: an arterial pH >7.55 is associated with a 
mortality rate of 45%, rising to 80% if >7.655. Most enzyme systems in our body are 
dependent on tight regulation of acid-base homoeostasis and we presume that 
besides the rickets, the initial obtunded state of our patient was also related to the 
extreme alkalosis, as it improved when pH decreased. Complications of prematurity 
can cause developmental delay in neonatal BS, but in our case the abnormal brain 
maturation may reflect the severe biochemical disturbance. 
Given these serious clinical difficulties, chiefly attributed to alkalosis, discussions 
were held about potential treatment approaches, including palliative care, bilateral 
nephrectomies with consequent renal replacement treatment, as well as titration 
with hydrochloric acid. At 10 months of age, a trial of amiloride was decided with the 
parents, with sufficient sodium supplementation to maintain volume homoeostasis. 
The drug was slowly increased to 1mg/kg/day. Within weeks, plasma bicarbonate 
levels decreased to between 27-47mmol/L with pH levels <7.6. Concurrently, the 
patient’s desaturations became less frequent, plasma phosphate levels normalized 
without supplementation and an improvement in general alertness was noted. The 
patient was eventually discharged home after her first birthday. She has shown 
some development, but remains severely delayed with last follow-up in September 
2015.  
The treatment of BS with potassium-sparing diuretics, such as amiloride is 
potentially hazardous, as mineralocorticoid activation is a critical mechanism to 
maintain euvolaemia. The kidneys regulate volume homoeostasis by tubular salt 
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handling and the mineralocorticoid-induced sodium reabsorption through the 
epithelial sodium channel (ENaC), which is coupled to secretion of potassium and 
protons, reflects the evolutionary importance of volume over acid-base and 
potassium homoeostasis. Although ENaC blockade by amiloride improves the 
metabolic alkalosis and hypokalaemia, it carries the risk of hypovolaemia. Yet, 
hyperaldosteronism may be uncoupled from volume homoeostasis in BS: renal 
volume sensing involves chloride reabsorption in the macula densa as the critical 
first step in tubuloglomerular feedback1. Decreased chloride transport leads to 
increased prostaglandin production with consequent renin-aldosterone activation. 
Since the macula densa is part of TAL, the molecular defect in chloride reabsorption 
in BS “shortcircuits” tubuloglomerular feedback.  Consequently, typical treatment 
includes prostaglandin synthesis inhibitors. However, neither indomethacin nor 
celecoxib treatment had resulted in substantial improvement in our patient, as 
previously reported in BS42. 
 
This case highlights the importance of the kidneys in maintaining homoeostasis and 
the severe consequences for whole body physiology, if the underlying molecular 
mechanisms are disrupted.  
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Figure 1: Selected traces from polysomnography 
 
Shown is a selected 3 min segment (scale bar 30 s) from the patient’s 
polysomnography at 8 months of age, before treatment with amiloride. Shown 
are traces for oxygen saturation (SpO2), heart rate, thoracic (Thor) and 
abdominal (Abdo) movement and transcutaneous pCO2 (tcpCO2). The 
indicated pressure levels of 60 and 90 mmHg are equivalent to 7.98 and 
11.97kPa, respectively. Note the persistently elevated tcpCO2 and the cyclical 
breathing pattern on the thoracic and abdominal movement traces, associated 
with dips in SpO2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
